Derace L. Schaffer Sells 15,000 Shares of Lantheus Holdings, Inc. (LNTH) Stock
Lantheus Holdings, Inc. (NASDAQ:LNTH) Director Derace L. Schaffer sold 15,000 shares of the company’s stock in a transaction dated Wednesday, September 13th. The shares were sold at an average price of $17.50, for a total transaction of $262,500.00. Following the completion of the transaction, the director now directly owns 48,730 shares of the company’s stock, valued at $852,775. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
Lantheus Holdings, Inc. (LNTH) opened at 17.15 on Friday. The stock has a market capitalization of $640.55 million, a PE ratio of 23.43 and a beta of 0.94. Lantheus Holdings, Inc. has a 52-week low of $7.61 and a 52-week high of $17.65. The firm has a 50-day moving average of $17.18 and a 200-day moving average of $15.49.
Lantheus Holdings (NASDAQ:LNTH) last announced its earnings results on Tuesday, August 1st. The medical equipment provider reported $0.42 EPS for the quarter, topping the consensus estimate of $0.24 by $0.18. The firm had revenue of $88.83 million for the quarter, compared to the consensus estimate of $80.56 million. Lantheus Holdings had a net margin of 8.44% and a negative return on equity of 37.47%. The business’s quarterly revenue was up 13.9% on a year-over-year basis. During the same quarter last year, the firm posted $0.24 EPS. On average, equities analysts expect that Lantheus Holdings, Inc. will post $1.12 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This story was first posted by Daily Political and is the property of of Daily Political. If you are reading this story on another website, it was illegally stolen and republished in violation of U.S. and international copyright & trademark legislation. The original version of this story can be viewed at https://www.dailypolitical.com/2017/09/16/derace-l-schaffer-sells-15000-shares-of-lantheus-holdings-inc-lnth-stock.html.
A number of research firms have weighed in on LNTH. BidaskClub cut shares of Lantheus Holdings from a “strong-buy” rating to a “buy” rating in a research report on Thursday, August 17th. Zacks Investment Research raised shares of Lantheus Holdings from a “hold” rating to a “strong-buy” rating and set a $18.00 price objective for the company in a research report on Thursday, August 3rd. Cantor Fitzgerald began coverage on shares of Lantheus Holdings in a research report on Monday, July 17th. They issued an “overweight” rating and a $22.00 price objective for the company. Jefferies Group LLC reissued a “buy” rating and issued a $18.00 price objective on shares of Lantheus Holdings in a research report on Friday, June 30th. Finally, Credit Suisse Group upped their price objective on shares of Lantheus Holdings from $14.00 to $19.00 and gave the company a “neutral” rating in a research report on Wednesday, August 2nd. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $18.60.
A number of institutional investors and hedge funds have recently made changes to their positions in LNTH. Marshall Wace North America L.P. raised its holdings in Lantheus Holdings by 1,214.5% in the 2nd quarter. Marshall Wace North America L.P. now owns 1,054,170 shares of the medical equipment provider’s stock worth $18,975,000 after acquiring an additional 973,977 shares during the period. Vanguard Group Inc. raised its holdings in Lantheus Holdings by 87.5% in the 2nd quarter. Vanguard Group Inc. now owns 1,478,350 shares of the medical equipment provider’s stock worth $26,093,000 after acquiring an additional 689,954 shares during the period. State Street Corp raised its holdings in Lantheus Holdings by 3,932.8% in the 2nd quarter. State Street Corp now owns 617,014 shares of the medical equipment provider’s stock worth $10,891,000 after acquiring an additional 601,714 shares during the period. Monashee Investment Management LLC bought a new position in Lantheus Holdings in the 1st quarter worth $5,313,000. Finally, Ameriprise Financial Inc. bought a new position in Lantheus Holdings in the 2nd quarter worth $7,396,000. Hedge funds and other institutional investors own 84.35% of the company’s stock.
About Lantheus Holdings
Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.
Receive News & Ratings for Lantheus Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.